Results from an open-label phase 2a study of cerdulatinib, a dual spleen tyrosine kinase/janus kinase inhibitor, in relapsed/refractory peripheral T-cell lymphoma
一项开放标签的 2a 期研究结果显示，双重脾酪氨酸激酶/Janus 激酶抑制剂 cerdulatinib 可用于治疗复发/难治性外周 T 细胞淋巴瘤。
期刊:Leukemia & Lymphoma
影响因子:2.2
doi:10.1080/10428194.2025.2455489
Horwitz, Steven M; Feldman, Tatyana A; Ye, Jing Christine; Khodadoust, Michael S; Munoz, Javier; Hamlin, Paul A; Kim, Youn H; Wilcox, Ryan A; Patel, Manish R; Coffey, Greg; Innes, Alison; Betz, Andreas; Holland, Jaymes; Guzman, Cristina B; Smith, Sonali M
